Personalis PE Ratio 2018-2024 | PSNL

Current and historical p/e ratio for Personalis (PSNL) from 2018 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Personalis PE ratio as of April 04, 2025 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Personalis PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2025-04-04 3.11 0.00
2024-12-31 5.78 $-1.37 0.00
2024-09-30 5.38 $-1.68 0.00
2024-06-30 1.17 $-1.64 0.00
2024-03-31 1.49 $-1.90 0.00
2023-12-31 2.10 $-2.25 0.00
2023-09-30 1.21 $-2.38 0.00
2023-06-30 1.88 $-2.36 0.00
2023-03-31 2.76 $-2.46 0.00
2022-12-31 1.98 $-2.48 0.00
2022-09-30 2.97 $-2.26 0.00
2022-06-30 3.45 $-2.08 0.00
2022-03-31 8.19 $-1.82 0.00
2021-12-31 14.27 $-1.48 0.00
2021-09-30 19.24 $-1.37 0.00
2021-06-30 25.30 $-1.24 0.00
2021-03-31 24.61 $-1.19 0.00
2020-12-31 36.61 $-1.19 0.00
2020-09-30 21.67 $-1.06 0.00
2020-06-30 12.97 $-1.01 0.00
2020-03-31 8.07 $-1.61 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.310B $0.085B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $17.427B 6.38
Dr Reddy's Laboratories (RDY) India $11.011B 21.00
BridgeBio Pharma (BBIO) United States $6.575B 0.00
Bausch Health Cos (BHC) Canada $2.381B 1.73
Supernus Pharmaceuticals (SUPN) United States $1.828B 17.06
Amphastar Pharmaceuticals (AMPH) United States $1.381B 8.33
Taysha Gene Therapies (TSHA) United States $0.285B 0.00
Assembly Biosciences (ASMB) United States $0.072B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00